FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> Roche | NHS | Herceptin

Expensive Herceptin draws fire in UK

Tools

Roche's drug Herceptin has become a lightning rod for debate over cancer treatment in England. Radiotherapists--including the specialty's chief at the National Health Service--are saying that cancer treatment is weighted too heavily toward expensive drugs and not enough toward more cost-effective radiation treatments.

The NHS spent some $206 million on Herceptin last year, and only 500 patients benefited from that chemotherapy, Dr. Peter Kirkbride told the BBC. Spending that kind of money on drugs means the NHS can't invest as much in radiation machines. For the same amount, Kirkbride said, he could have treated 30,000 cancer patients with radiation.

Predictably, radiation-machine manufacturers aren't pleased, either; a trade group spokesman says there's been a "collapse in critical investment." How much of this debate is evidence-based outrage and how much sour grapes? We'll let the NHS decide.

- read the BBC's report

Related Articles:
Roche's Herceptin KO's tumors. Report
UK accepts J&J's money-back guarantee. Report
Roche cuts UK price on cancer drug. Report

More stories about Roche   NHS   Herceptin  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 11 + 58?
To combat spam, please solve the math question above.